What’s New for Prurigo Nodularis Patients?
With two new U.S. Food and Drug Administration-approved therapies and a rich pipeline, prurigo nodularis (PN) is finally getting the attention it deserves.Adam Friedman, MD, Professor and Chair of Dermatology at the George Washington School of Medicine and Health Sciences in Washington, DC, discusses the new thinking about PN.